KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy
Authors
Masfarre, L.Rocha, P.
Clave, S.
Moliner, L.
Navarro-Gorro, N.
Rios-Hoyo, A.
Sanchez, I.
Giner, M.
Corbera, A.
Taus, A.
Bellosillo, B.
Arriola, E.
Issue Date
2022
Metadata
Show full item recordCitation
Masfarré L, Rocha P, Clavé S, Moliner L, Navarro-Gorro N, Ríos-Hoyo A, et al. 167P KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy. Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S109.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.02.199Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.02.199Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.02.199